Comparing aspheric IOLs


George Beiko compares AMO's Tecnis and Alcon's IQ aspheric IOLs to establish which model provides the best vision.

Key Points

"A number of studies examining contrast sensitivity have already established the superiority of aspheric over traditional IOLs in terms of functional vision,"1–6 asserted Professor George Beiko, of McMaster University, Canada.

Aspheric IOLs provide better visual function because they correct the natural corneal spherical aberration, which, according to Professor Beiko, is 0.27–0.30 µm, on average. Correcting this aberration has been shown to improve contrast sensitivity; different aspheric lenses, however, aim to provide different levels of specific aberrations postoperatively, and there is no literature proving the most desirable degree of postoperative aberration.

How do the lenses compare?

AMO's Tecnis has a wavefront designed aspheric surface, and is a three-piece foldable, UV-blocking hydrophobic acrylic lens with an optimal refractive index of 1.47. It is available, in 0.5 D increments, for +10 to +30 D of correction.

Alcon's IQ lens has a posterior aspheric surface and a square edge; it is a one-piece foldable, UV-blocking and blue light-filtering hydrophobic acrylic lens with an optimal refractive index of 1.55. It is available, in 0.5 D increments, for +6 to +30 D of correction.

Both lenses have an overall lens length of 13.0 mm.

"The AMO lens targets a postop spherical aberration of 0.00 µm, whereas the Alcon lens's target is 0.10 µm," Professor Beiko explained. "We implanted the lenses into patients with corneal spherical aberrations of approximately 0.27 µm and compared the postoperative visual outcomes."

Measuring visual outcomes objectively

Forty patients with similar preoperative profiles were randomly assigned to receive either the Tecnis or the IQ lens. The spherical aberration of the anterior corneal surface had been determined using the Oculus Easygraph. To maintain consistency, a single surgeon using the same technique in each case was used to perform all the implantations. Each patient received the same postoperative care.

"At a minimum of eight weeks after the implantation, distance corrected contrast sensitivity was measured with an Optec 6500, and we used ANOVA analysis to compare all readings," Professor Beiko clarified.

"The study groups were found to be similar in terms of age, pupil size under photopic and mesopic conditions, post-op vision and post-op refractive error. According to our findings, there was a trend for the Tecnis group to outperform the IQ group under photopic conditions, but statistical significance was not reached," explained Professor Beiko (Figure 1/Table 2). However, under mesopic conditions, the Tecnis group had greater contrast sensitivity at 3, 12 and 18 cpd (p = 0.05) and at 6 pcd (p = 0.10) (Figure 2/Table 3).

Tecnis offers superior outcomes

Overall, the results tended to show that implanting an aspheric IOL that aimed to produce a smaller postoperative spherical aberration provided a better mean contrast sensitivity result and sharper vision.

"In terms of provision of functional vision, we therefore found the AMO Tecnis IOL to be the superior lens," Professor Beiko concluded.


Special ContributorGeorge H. H. Beiko, BM, BCh, FRCSC is an assistant clinical professor of ophthalmology at McMaster University, Ontario, Canada. He may be reached by E-mail:
Professor Beiko has disclosed financial relationships with AMO and Alcon Laboratories.


1. M. Packer, et al. J. Refract. Surg. 2002;18:692–696.

2. U. Mester, et al. J. Cataract Refract. Surg. 2003;29(4):652–660.

3. R.M. Kershner. J. Cataract Refract. Surg. 2003;29(9):1684–1694.

4. H. Kennis, et al. Bull. Soc. Belge Ophtalmol. 2004;294:49–58.

5. A. Martinez Palmer, et al. Arch. Soc. Esp. Oftalmol. 2005;80(2):71–78.

6. R. Bellucci, et al. J. Cataract Refract. Surg. 2005;31:712–717.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.